Brief Report RED CELLS, IRON, AND ERYTHROPOIESIS A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT
نویسندگان
چکیده
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia that results from the expansion of hematopoietic stem cells that are deficient for glycosylphosphatidylinositol (GPI), a glycolipid moiety that anchors .100 different proteins to the cell surface. PNH patients were reported to be deficient for an initial step in the GPI anchor synthesis that is catalyzed by the GPI-GlcNAc transferase, and somatic mutations in the X-chromosomal gene PIGA that encodes a subunit of this transferase complex are regarded as the causative event in the predominant number of PNH cases. However, in a small number of PNH cases with a clear GPI anchor deficiency, no mutations in PIGA have been found. In this work, we report about 2 mutation events, a germline splice site mutation and a somatic deletion in PIGT, which is another gene of the GPI anchor synthesis pathway, that we identified performing next-generation sequencing in a PNH patient with wild-type PIGA.
منابع مشابه
Clinical studies on iron kinetics. I. Iron-kinetics studies in blood disorders.
Ferrokinetics data on patients with blood disorders of diverse etiology were presented and the clinical implication of this test was discussed. Ferrokinetics data on normal adults as well as on the aged were also presented. Ferrokinetic patterns of ineffective erythropoiesis were obtained on patients with pernicious anemia, erythroleukemia, myelofibrosis, paroxysmal nocturnal hemoglobinuria and...
متن کاملRED CELLS, IRON, AND ERYTHROPOIESIS A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement
The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is chronic intravascular hemolysis that is a consequence of unregulated activation of the alternative pathway of complement (APC). Intravascular hemolysis can be inhibited in patients by treatment with eculizumab, a monoclonal antibody that binds complement C5 thereby preventing formation of the cytolytic membrane attack complex...
متن کاملRED CELLS, IRON, AND ERYTHROPOIESIS Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
1Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples; 2Laboratory of Genetics and Gene Transfer, Core Research Laboratory–Istituto Toscano Tumori (CRL-ITT), Florence; 3Hematology, University of Florence, Florence; 4Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome; 5Department of Hematology, Istituto di Ricovero e ...
متن کاملRED CELLS, IRON, AND ERYTHROPOIESIS Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity
Glucocorticoids are used extensively to treat autoimmune hemolytic anemias. Some beneficial effects of glucocorticoid pulse therapy have also been reported in sickle cell disease and paroxysmal nocturnal hemoglobinuria. Based on established concepts of hemoglobin (Hb) toxicity and physiologic Hb scavenger systems, we evaluated whether glucocorticoids could support an adaptive response to extrac...
متن کاملIdentification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
Patients with non-transfusion-dependent thalassaemia (NTDT) have a genetic defect or combination of defects that affect haemoglobin synthesis, but which is not severe enough to require regular blood transfusions. The carrier frequency of NTDT is high (up to 80% in some parts of the world) but the prevalence of symptomatic patients varies with geography and is estimated to be from 1 in 100,000 t...
متن کامل